KIR3DL1 and rhabdomyosarcoma: Activating KIR gene content has been associated with increased NK potency against a panel of pediatric tumors including Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, lymphoma, leukemia, and brain tumors suggesting that KIR mismatch alone is not enough to predict efficacy of NK cell adoptive therapy [36].